Top News

• Patient Injured in Intellias Phase 3 nex-z Trial Dies
• FDA 483 Cites Quality Deficiencies at Indian Drug Plant
• FDA Posts Biohaven Troriluzole Complete Response Letter
• FDA Extends Review of Rhythms Setmelanotide sNDA
• FDA OKs Darzalex Faspro for Smoldering Multiple Myeloma
• Senate Democrats Caution FDA on Mifepristone Review
• Baxter Oncology FDA-483 Out
• 76 New or Revised Product-Specific Guidances Out